Generated by Codex with GPT-5

This summary covers The Economist’s May 9th, 2026 Science & technology article on peptideins, published under the headline Almost proteins and listed in the contents as Proteins' little cousins.

The article describes a newly named class of tiny molecules that could complicate the standard picture of how human cells work. Peptideins resemble proteins but are smaller and, in most cases, have no known function. That uncertainty is the point. They may turn out to be mostly biological noise, or some may become useful clues to disease and promising targets for cancer treatments. Giving them a name is an attempt to make researchers pay closer attention.

Beyond The Familiar Proteome

The conventional story of cellular activity is straightforward. Enzymes copy stretches of DNA into RNA. Ribosomes read the RNA as a blueprint and assemble chains of amino acids called peptides. Some peptides are classified as proteins: relatively large molecules with recognised functions, often found across multiple species. Scientists have identified about 19,500 human proteins, including familiar examples such as insulin, which helps regulate blood sugar, and p53, which responds to DNA damage and can suppress cancer.

For years, researchers concentrated on the parts of the genome known to encode these proteins. Much of the rest was dismissed as junk. Better tools have made that view harder to sustain. Ribosome profiling can reveal where the cell’s protein-making machinery is active on RNA strands. Sensitive mass spectrometry can detect extremely small molecules in cell samples. Together, these techniques have shown that translation may be taking place far beyond the regions associated with established genes.

The result is a growing catalogue of microproteins, sometimes called the dark proteome. A team co-led by Sebastiaan van Heesch of the Princess Maxima Centre in the Netherlands pooled previous experimental results to produce the most detailed map yet. The researchers confirmed 1,785 microproteins. Around 65% contain fewer than 50 amino acids, making them smaller than more than 99% of recognised human proteins.

Some microproteins already appear biologically significant. One is involved in the progression of medulloblastoma, a childhood brain cancer. Another, humanin, protects cells from stress and may be connected to healthy ageing and neurodegenerative disease. But most have not yet been linked to any concrete effect. The researchers propose calling this poorly understood group peptideins.

A Useful Category Or A Passing Name

The most intriguing possibility is that peptideins could expose new ways to treat cancer. Some appear on the outside of tumour cells, where the immune system may be able to recognise them. That could make them useful targets for immunotherapy drugs or vaccines designed to direct the body’s defences toward cancerous cells. Other peptideins might regulate genes or influence signalling between cells.

The evidence remains preliminary. Ribosome profiling can produce false positives: apparent translation in an unexpected location may be an experimental illusion. The study identified thousands of possible peptideins that could not yet be confirmed. Even among genuine peptideins, many may prove unimportant. One cell biologist quoted by the article doubts that more than a few hundred will turn out to be useful.

That caution does not make the search trivial. Science often advances by noticing what an old framework treated as irrelevant. Peptideins are a reminder that the human genome still contains poorly understood activity at a very small scale. Whether the new label lasts will depend on whether these almost-proteins lead researchers to important biology that the familiar map left out.